Innovent Biologics, Inc. (IVBXF) Stock Price & Analysis
Innovent Biologics, Inc. (IVBXF) — price $10.93 (0.00%), as of the Nov 19, 2026 trading session; market cap $19.1B. Expected results Mar 31, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Innovent Biologics, Inc. · IVBXF · Healthcare · Biotechnology
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.93 | |
| Change on the day | 0.00% | |
| 52-week range | $9.10–$15.01 | |
| Market capitalisation | $19.1B | — |
| Price / earnings (trailing) | 99.12 | |
| Shares traded on the day | 900 | |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Innovent Biologics (IVBXF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Innovent Biologics (IVBXF), and what does it report?
Short answer
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. Innovent Biologics, Inc. (IVBXF) is classified as Healthcare / Biotechnology. SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 7,502 people and is led by De-Chao Yu. In Q2 FY2026 it reported revenue of CN¥8.50B and net income of CN¥1.24B. The market values it at $19.1B.
What do the latest results show for Innovent Biologics (IVBXF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥8.50B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.27B Aug 25, 2026
- Latest report · revenue estimate
- $1.31B Aug 25, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 25, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 25, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 25, 2026 | $1.27B | $1.31B | $0.1030 | $0.0692 |
| Mar 26, 2026 | $1.01B | $985.90M | −$0.0014 | $0.0172 |
| Aug 27, 2025 | $830.16M | $790.35M | $0.0687 | $0.0251 |
| Mar 26, 2025 | $749.12M | $637.09M | $0.0250 | −$0.0315 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥8.50B | CN¥1.24B | CN¥0.68 (diluted) |
| Q4 FY2025 | CN¥6.97B | -CN¥20M | -CN¥0.02 (diluted) |
| Q2 FY2025 | CN¥5.95B | CN¥834M | CN¥0.49 (diluted) |
| Q4 FY2024 | CN¥5.47B | CN¥298M | CN¥0.18 (diluted) |
What are the financial strengths and risks for Innovent Biologics (IVBXF)?
Short answer · as of
The distress and quality screens read Altman Z 4.21 · Piotroski F 7. Trailing ratios: ROE 7.0% · ROA 2.2% · current ratio 2.68.
What should you watch next at Innovent Biologics (IVBXF)?
Short answer · as of
The next earnings report is expected on Mar 31, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IVBXF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IVBXF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Innovent Biologics (IVBXF) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the IVBXF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IVBXF a good stock to buy?
Stock Expert AI does not rate IVBXF buy, sell or hold. Innovent Biologics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IVBXF stock price today?
The last price recorded for Innovent Biologics, Inc. (IVBXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for IVBXF?
Innovent Biologics, Inc. faces several key risks inherent to the biopharmaceutical industry and its market position. A primary risk is the high failure rate associated with clinical trials; any setbacks or failures in its extensive pipeline could lead to significant financial losses and delays in bringing new therapies to market.
What are the key factors to evaluate for IVBXF?
Evaluate IVBXF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. For example, collaborations can facilitate co-development of novel therapies or provide pathways for international commercialization, expanding Innovent's reach beyond China. Not financial advice.
How frequently does IVBXF data refresh on this page?
IVBXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IVBXF's recent stock price performance?
Innovent Biologics, Inc. (IVBXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified pipeline of antibody drug candidates across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVBXF overvalued or undervalued right now?
The trailing P/E of Innovent Biologics, Inc. (IVBXF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IVBXF before investing?
Before investing in Innovent Biologics, Inc. (IVBXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 39 figures on this page — 1 from SEC filings and earnings calls, 32 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com